Floatz logo

Busulphan

Blasts Under 25 Percent of Bone Marrow Nucleated Cells

Fred Hutchinson Cancer CenterPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Blasts Under 25 Percent of Bone Marrow Nucleated Cells cohort.

Asset / SponsorPhaseRating
Romidepsin
Fred Hutchinson Cancer Center
Phase 2CCC

Same molecule, other indications

Busulphan is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
graft versus host diseaseDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →